Get the Stockscreener App
1.45
1.40%
0.02
After Hours:
1.40
-0.05
-3.45%
iBio Inc stock is traded at $1.45, with a volume of 1.05M.
It is up +1.40% in the last 24 hours and down -13.17% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$1.43
Open:
$1.44
24h Volume:
1.05M
Relative Volume:
1.08
Market Cap:
$72.03M
Revenue:
$300.00K
Net Income/Loss:
$-27.61M
P/E Ratio:
-2.51
EPS:
-0.5777
Net Cash Flow:
$-22.17M
1W Performance:
+5.84%
1M Performance:
-13.17%
6M Performance:
-36.40%
1Y Performance:
+97.79%
1-Day Range:
$1.35
$1.47
1-Week Range:
$1.31
$1.47
52-Week Range:
$0.5562
$3.82
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.45 | 71.04M | 300.00K | -27.61M | -22.17M | -0.5777 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-26 | Initiated | Raymond James | Outperform |
| Jun-05-26 | Initiated | B. Riley Securities | Buy |
| Oct-21-25 | Initiated | Oppenheimer | Outperform |
| Oct-17-25 | Initiated | Leerink Partners | Outperform |
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
View All
iBio Inc Stock (IBIO) Latest News
iBio Inc (IBIO) Cash Flow - TradingKey
iBio Inc (IBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
iBio Inc (IBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
iBio Inc (IBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
iBio, Inc. Revenue Breakdown – TRADEGATE:0JV0 - TradingView
iBio Inc (IBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Affinity Asset Advisors LLC Grows Position in iBio, Inc. $IBIO - MarketBeat
iBio Inc (IBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
iBio Inc (IBIO) Institutional Confidence - TradingKey
Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
IBIO|iBio Inc|Price:1.395|Chg%:+0.015 - TradingKey
iBio Updates Governance Deadlines for 2026 Annual Meeting - The Globe and Mail
iBio (NYSE: IBIO) schedules 2026 meeting, updates proposal deadlines - Stock Titan
iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
iBio (NASDAQ:IBIO) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
iBio Inc. Holds Steady at $1.51 as Biotech Stock Consolidates Near Key LevelsSupply Zone - dars.gov.et
We Think iBio (NASDAQ:IBIO) Can Afford To Drive Business Growth - Sahm
iBio Inc. (IBIO) Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre‑Revenue PhaseBanking Earnings Report - DonanımHaber
iBio Inc. (IBIO) Retreats 1.85%, Approaching Key Support at $1.51Narrow Range Breakout - DonanımHaber
Price to sales forward of iBio, Inc. – NASDAQ:IBIO - TradingView
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO) - The Globe and Mail
IBIO Maintained by Chardan Capital -- Price Target Stays at $5.0 - GuruFocus
IBIO News | IBIO INC (NASDAQ:IBIO) - ChartMill
IBIOiBio Inc Latest SEC Filings - Finviz
$IBIO stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
iBio’s IBIO-610 Antibody Achieves 98% Activin E Inhibition and Boosts Fat Loss in Obese Primates, Outperforming Semaglutide Alone 1 - Minichart
iBio Highlights Promising New Preclinical Obesity Antibody Data - TipRanks
Innovative Findings on IBIO-610 from iBio - GuruFocus
iBio (NASDAQ: IBIO) obesity antibody cuts Activin E and spares lean mass - Stock Titan
iBio Inc. announced research results showing that a single administration of the candidate drug IBIO-610 in an obese non-human primate model achieved nearly complete inhibition of active activin E for up to eight weeks. - Bitget
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study - The Manila Times
Single dose of IBIO-610 antibody shows 98% Acti... - Pluang
IBio, Inc.(NasdaqCM: IBIO) added to Russell Microcap Value Benchmark Index - marketscreener.com
IBio, Inc.(NasdaqCM: IBIO) added to Russell 3000E Index - marketscreener.com
IBio, Inc.(NasdaqCM: IBIO) added to Russell Microcap Index - marketscreener.com
iBio Inc. (IBIO) Surges Over 5% on Renewed Biotech Interest – Key Levels in FocusNegative Gamma - dars.gov.et
Enterprise value to revenue forward of iBio, Inc. – NASDAQ:IBIO - TradingView
Price to book forward of iBio, Inc. – NASDAQ:IBIO - TradingView
Enterprise value to EBIT forward of iBio, Inc. – NASDAQ:IBIO - TradingView
How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery - Fierce Biotech
iBio, Inc. Actuals & Estimates (NASDAQ:IBIO) - TradingView
0JV0 Forecast — Price Target — Prediction for 2027 - TradingView
IBIO Forecast — Price Target — Prediction for 2027 - TradingView
iBio Inc. (IBIO) Slips 1.23% — Stock Tests Support Zone Amid Low VolumeTrend Reversal Picks - dars.gov.et
iBio Inc. Q1 2026 Earnings: EPS Beat Mitigates Broader Market ConcernsProfit Inflection Point - dars.gov.et
Top iBio (IBIO) Competitors 2026 - MarketBeat
IBIO Q1 2026 Earnings: Narrowed Loss Per Share Exceeds Expectations, Stock Responds PositivelyPerformance Review - DonanımHaber
iBio Inc (IBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
iBio Inc (IBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
iBio Inc (IBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):